Evoq Remedies Ltd - 543500 - Corporate Insolvency Resolution Process (CIRP)-Admission of application by Tribunal
Evoq Remedies has been admitted into the Corporate Insolvency Resolution Process (CIRP) by NCLT Ahmedabad. This follows an application from an operational creditor regarding an unpaid debt of Rs.1.95 crore, leading to a moratorium on company assets.
Jun 11 2026 17:15:30
Evoq Remedies Ltd - 543500 - Corporate Insolvency Resolution Process (CIRP)-Admission of application by Tribunal
Evoq Remedies faces an application for Corporate Insolvency Resolution Process (CIRP) filed by an operational creditor, Harbhole Agrotech. The application has been submitted to the National Company Law Tribunal (NCLT), Ahmedabad.
Jun 10 2026 18:11:14
Evoq Remedies Ltd - 543500 - Integrated Filing (Finance) For The Half Year And Year Ended On 31St March, 2026
Evoq Remedies received a qualified audit opinion with material uncertainty regarding its ability to continue as a going concern for FY26. The auditor noted non-compliance with related party transactions, unconfirmed debtor balances, significant tax demands, an ongoing SEBI investigation, and severely curtailed operations.
May 30 2026 19:44:22
Evoq Remedies Ltd - 543500 - Appointment Of M/S. Jay Pandya & Associates (FRN: S2024GJ963300), Company Secretaries, Ahmedabad, As Secretarial Auditor Of The Company For The Financial Year 2025-26.
Evoq Remedies' auditor issued a qualified opinion with material uncertainty about the company's ability to continue as a going concern. Key issues include non-compliant related party loans, unconfirmed debtor/supplier balances, unpaid statutory dues (income tax, TDS, GST demand), lack of internal auditor, cash losses, and an active SEBI investigation concerning financial statements and preferential issue proceeds.
May 30 2026 19:42:17
Evoq Remedies Ltd - 543500 - Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. Saturday, 30Th May, 2026 And Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Evoq Remedies reported H1 FY26 net loss of ₹29.42 lakhs. The auditor issued a qualified opinion due to material uncertainty about going concern, related party loan non-compliance, unconfirmed debtor balances, and an ongoing SEBI investigation.
May 30 2026 19:33:26
Evoq Remedies Ltd - 543500 - Board Meeting Intimation for Intimation For Rescheduling Of Board Meeting From 27Th May, 2026 To 30Th May, 2026
Evoq Remedies Board meeting, originally scheduled for May 27, 2026, has been rescheduled to May 30, 2026. The board will consider audited financial results for the half year and full year ended March 31, 2026, along with the Auditor's Report.
May 27 2026 12:42:42
Read More